All In Biotech

NDA 208630 · Nxdc

Gleolan

Aminolevulinic Acid Hydrochloride · Oral

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 23, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jun 6, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

200

40 Phase 3, 19 recruiting

FAERS reports

161

83 serious, 7 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 29, 2026.

Gleolan is indicated in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery. Gleolan is an optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. ( 1 )

Mechanism: ALA occurs endogenously as a metabolite that is formed in the mitochondria from succinyl-CoA and glycine. Exogenous administration of ALA leads to accumulation of the ALA metabolite PpIX in tumor cells. The reason for the accumulation of PpIX in neoplastic brain tissue is not known. During glioma surgery, Gleolan is used with an operating microscope adapted with a blue emitting light source (power density 40-80 mW/cm 2 ) and filters for excitation light of wavelength 375 to 440 nm, and observation at wavelengths of 620 to 710 nm. This allows tumor tissue to be visualized as red fluorescence....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 6, 2017 Original approval · Type 3 - New Dosage Form · priority review OrphanLabelLetterReview
1 products under this application
  • GLEOLAN · AMINOLEVULINIC ACID HYDROCHLORIDE 1.5GM/VIAL · FOR SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Aminolevulinic Acid" as an intervention, any sponsor and status, largest first.

All 200 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective46
  • hypotension31
  • vomiting11
  • inappropriate schedule of product administration9
  • cardiac arrest7
  • nausea7
  • photosensitivity reaction7
  • blood pressure decreased6
  • seizure6
  • atrial fibrillation5
  • hepatic function abnormal5
  • loss of consciousness5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20142
20152
20182
201927
202019
20216
202218
202324
202427
202519
202614

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 550 on PubMed

Sponsor: Nxdc

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.